NasdaqGM:CRSPBiotechs
Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP)
CRISPR Therapeutics AG recently reported its second-quarter and six-month 2026 results, with revenue rising to US$10.18 million for the quarter and its quarterly net loss narrowing to US$91.15 million compared with the prior year.
The company also showed a lower basic loss per share from continuing operations, suggesting that its cost structure and funding profile may be evolving as programs advance.
We will now examine how this sharp improvement in revenue alongside a reduced net loss...